Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002837 · ClinicalTrials.gov registry record · Phase 1
High-Dose Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT00002837: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00002837 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 21 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002837, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining peripheral stem cell transplantation with chemotherapy may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of high-dose combination chemotherapy and peripheral stem cell transplantation in treating patients with recurrent or metastatic breast cancer.
Interventions
- DRUG Cyclophosphamide
- DRUG Paclitaxel
- DRUG Doxorubicin Hydrochloride
- PROCEDURE Peripheral Blood Stem Cell Transplantation
- BIOLOGICAL Filgrastim (G-CSF)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 1995-09 |
| Est. Completion | 2002-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002837
The ClinicalTrials.gov registry entry for NCT00002837 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT00002837 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002837 about?
NCT00002837 is a clinical study titled "High-Dose Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining peripheral stem cell transplantation with chemotherapy may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of high-dose combination chemother...
What is the current status of trial NCT00002837?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 1995-09. Estimated completion is 2002-01.
What interventions are being tested in trial NCT00002837?
The interventions under investigation include: Cyclophosphamide (DRUG), Paclitaxel (DRUG), Doxorubicin Hydrochloride (DRUG), Peripheral Blood Stem Cell Transplantation (PROCEDURE), Filgrastim (G-CSF) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00002837?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.